Twist Bioscience Corporation (TWST)
| Market Cap | 8.29B +353.5% |
| Revenue (ttm) | 431.80M +19.2% |
| Net Income | -136.72M |
| EPS | -2.23 |
| Shares Out | 62.71M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,719,274 |
| Open | 133.44 |
| Previous Close | 135.34 |
| Day's Range | 125.01 - 138.06 |
| 52-Week Range | 23.30 - 219.71 |
| Beta | 2.22 |
| Analysts | Buy |
| Price Target | 168.25 (+27.34%) |
| Earnings Date | Nov 12, 2026 |
About TWST
Twist Bioscience Corporation manufactures and sells synthetic DNA-based products. It offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglo... [Read more]
Financial Performance
In fiscal year 2025, Twist Bioscience's revenue was $376.57 million, an increase of 20.32% compared to the previous year's $312.97 million. Losses were -$77.67 million, -62.79% less than in 2024.
Financial StatementsAnalyst Summary
According to 13 analysts, the average rating for TWST stock is "Buy." The 12-month stock price target is $168.25, which is an increase of 27.34% from the latest price.
News
Twist Bioscience to Present at Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that Emily M. Leproust, Ph.D., CEO and co-foun...
Twist Bioscience down 12% to $125.16 after Hunterbrook report
10:42 EST Twist Bioscience (TWST) down 12% to $125.16 after Hunterbrook report
Twist could repeat its 95% stock collapse, says Hunterbrook CEO
Hunterbrook CEO Nathaniel Horwitz argues in an article for The Bear Cave that Twist Bioscience (TWST) may be overvalued, despite rapid growth and renewed investor enthusiasm tied to its work…
Notice of Proposed Derivative Settlement: Twist Bioscience Corporation
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST): UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE IN RE TWIST BIOSCIENCE CORPORATION DERIVATIVE LITIGATION Le...
Twist Bioscience announces launch of Twist MRD Express
Twist Bioscience (TWST) launched Twist MRD Express. Twist MRD Express custom panels enable cancer researchers to investigate tumor-associated genomic variants and support studies in oncology research,...
Twist Bioscience Launches MRD Express with Rapid Turnaround Time
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today launched Twist MRD Express, custom panels manufactured at s...
Twist Bioscience expands portfolio with Twist Express Screening Antibodies
Twist Bioscience (TWST) expanded its antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies. “As AI-guided drug discovery approaches dramatically expa...
Twist Bioscience expands portfolio with Twist Express Screening Antibodies
Twist Bioscience (TWST) expanded its antibody production and characterization portfolio with the launch of Twist Express Screening Antibodies. “As AI-guided drug discovery approaches dramatically expa...
Twist Bioscience Expands High-Throughput Antibody Characterization with Launch of Express Screening Antibodies
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today expanded its antibody production and characterization portf...
Twist Bioscience to Report Fiscal 2026 Fourth Quarter and Full Year Financial Results on Thursday, November 12, 2026
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value healthcare company, today announced that it will issue its financial results for t...
Twist Bioscience price target raised to $190 from $115 at TD Cowen
TD Cowen raised the firm’s price target on Twist Bioscience (TWST) to $190 from $115 and keeps a Buy rating on the shares. The firm adjusted targets in the life…
Twist Bioscience price target raised to $205 from $120 at Canaccord
Canaccord raised the firm’s price target on Twist Bioscience (TWST) to $205 from $120 and keeps a Buy rating on the shares. The firm sees increasing utilization of and a…
Twist Bioscience initiated with a Hold at Jefferies
Jefferies initiated coverage of Twist Bioscience (TWST) with a Hold rating and $150 price target Twist is a synthetic biology company that manufactures synthetic DNA and DNA-based products using propr...
Twist Bioscience price target raised to $215 from $112 at Barclays
Barclays raised the firm’s price target on Twist Bioscience (TWST) to $215 from $112 and keeps an Overweight rating on the shares. The firm adjusted targets in the life science…
Twist Bioscience falls -12.7%
Twist Bioscience (TWST) is down -12.7%, or -$26.00 to $179.00.
Twist Bioscience price target raised to $212 from $107 at Guggenheim
Guggenheim raised the firm’s price target on Twist Bioscience (TWST) to $212 from $107 and keeps a Buy rating on the shares. The firm adjusted its models and forecasts for…
The Top HealthTech Questions Landing on Our Desks
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled th...
Twist Bioscience price target raised to $190 from $160 at Leerink
Leerink analyst Puneet Souda raised the firm’s price target on Twist Bioscience (TWST) to $190 from $160 and keeps an Outperform rating on the shares. The firm cites peer group…
Twist Bioscience rises 6.9%
Twist Bioscience (TWST) is up 6.9%, or $10.88 to $169.38.
Twist Bioscience price target raised to $160 from $120 at Leerink
Leerink analyst Puneet Souda raised the firm’s price target on Twist Bioscience (TWST) to $160 from $120 and keeps an Outperform rating on the shares. The firm’s meetings with Twist’s…
Twist Bioscience enters agreement with Lilly TuneLab
Twist Bioscience Corporation (TWST) announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Company (LLY). Twist is a provider of antibody cha...
Twist Bioscience Joins Lilly TuneLab to Advance Antibody Drug Discovery
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collaborative ...
Twist Bioscience says Anthropic pilot work factored in FY27 orders expectations
Emily Leproust, the co-founder and CEO of Twist, was asked while presenting at the Baird Global Healthcare Conference about Twist having recently been named an independent evaluator chosen to produce…
Twist Bioscience Transcript: 2026 Global Healthcare Conference
Miniaturized DNA synthesis technology is driving rapid growth, with expanding applications in diagnostics and therapeutics. AI-driven drug discovery and data services are key growth drivers, supported by strong customer demand and strategic partnerships. Profitability is targeted for Q4, with long-term plans for sustained high growth and margin expansion.